CONSHOHOCKEN, Pennsylvania
,
April 7, 2022
(press release)
–
AmerisourceBergen, a global healthcare solutions company, today announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will invest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals globally. AB Health Ventures will build on AmerisourceBergen’s ongoing commitment to delivering innovation for its customers. “I believe that innovation is the catalyst to sustained progress and change, which is why AmerisourceBergen is committed to taking bold, innovative actions to achieve our purpose and drive long-term growth,” said Steve Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen. “Over the years, we have made thoughtful and strategic investments to advance the development and delivery of healthcare, enable access and create even stronger stability across the supply chain. The creation of AB Health Ventures will build on our track record of success as we identify meaningful partnerships that will bring emerging healthcare solutions to market and create healthier futures for all.” AB Health Ventures will initially launch with $150 million allocated for investment in early-to mid-stage health-related startups around the world. The fund will prioritize investments in entrepreneurs who are pursuing bold ideas in areas such as the future of pharmacy and distribution, clinical development and commercialization of pharmaceuticals, practice solutions for healthcare providers, and animal health. AB Health Ventures is a wholly-owned subsidiary of AmerisourceBergen that will utilize the company's deep expertise, global footprint, and strong relationships with stakeholders across the pharmaceutical supply chain to add value to entrepreneurs looking for partners to help grow their businesses. AmerisourceBergen will support startups in helping them rapidly prototype solutions, test with pilots, and accelerate scale through commercialization. “The unprecedented achievements and advancements across the healthcare industry are remarkable and undeniable. AmerisourceBergen is eager to build on this momentum and ultimately accelerate further innovation by working with entrepreneurs who are looking to revolutionize healthcare. With the launch of AB Health Ventures, we can unlock new ideas, generate additional value and put forward potential solutions that will benefit our customers and the patients they ultimately serve,” said Leslie Donato, EVP, Chief Strategy Officer at AmerisourceBergen. AmerisourceBergen has a successful history of partnerships and minority investments in like-minded startups, delivering strong commercial benefits to improve customer and ultimately patient outcomes. Most recently, AmerisourceBergen partnered with TrakCel, a leading innovator of cellular orchestration solutions, and Annexus Health, a healthcare technology company that is enhancing the patient journey by reducing financial and administrative burdens to improve access, speed and adherence. Touchdown Ventures, a firm specializing in corporate venture capital, will help manage the AB Health Ventures fund. Touchdown will work closely with senior executives of AB in all aspects of operating the fund. Additional information about AB Health Ventures can be found atwww.abhealthventures.com About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 42,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at www.amerisourcebergen.com.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
